August 26, 2026

How Do Equity Analysts Value Public Biotechs?

Valuing a commercial-stage industrial company is relatively straightforward: revenue, margins, cash flow, and comparable multiples provide a familiar framework.

Biotech has none of that. Which is why equity analysts rely on a hybrid toolkit that blends probability-weighted forecasting with peer-based reality checks.

What follows is a practical look at how The Street approaches biotech valuations – and how management teams can influence the outcome of those deliberations.

1. The foundation: risk-adjusted DCF models

Most reputable healthcare analysts anchor their valuation of a biotech on a risk-adjusted discounted cash flow (rNPV) model. Unlike traditional DCFs, these models account for the uncomfortable truth that most drugs never make it to market.

Analysts typically forecast:

• Peak sales by indication (or potentially asset).
• Launch timing.
• Pricing, penetration and market share assumptions.
• Development costs and commercialization expenses.
• Patent life and resulting exclusivity.

Going through the development pipeline program by program, they then apply a probability of success at each development stage before discounting future cash flows back to present value.

Drug failures and the probability of success

Based on historical data from thousands of drug programs across decades, analysts can estimate the probability that a drug moves on from its current development phase:

Drug Transition	Probability
Phase 1 → Phase 2	~50%+
Phase 2 → Phase 3	~25–30%
Phase 3 → NDA/BLA	~55–60%
Phase 1→ Approval	~8–12%

Source: BIO/BioMed tracker

From this, one can therefore determine the likelihood of a development candidate eventually becoming an approved drug at any given timepoint:

Clinical Stage of Program	Risk Description	Probability that Drug is Approved
Phase 1 underway	High attrition risk	10-20%
Phase 2 underway	Scientific risk begins to narrow	25-40%
Phase 3 underway	Late-stage data reduces uncertainty	50-70%

Source: BIO/ BioMed tracker

Note: these percentages are not static truths – they reflect historical averages across all trials. A strong mechanism of action, biomarker strategy, or regulatory precedent can materially shift these assumptions.

In addition, in therapeutics areas like infectious disease and endocrinology, early success tends to be much more predictive of late-stage efficacy than in, say, oncology.   

2. Peer comparisons: the reality check

Even the most elegant rNPV model rarely stands alone. Analysts almost always cross-reference their work against peer comparisons.

Common benchmarks include:

• Enterprise value per pipeline asset.
• Market cap relative to clinical stage.
• EV/Sales multiples.
• Valuation versus companies targeting similar indications.

Peer analysis serves two purposes:

• It prevents valuation models from drifting too far from market sentiment.
• It also helps analysts defend their numbers internally – a price target that looks wildly inconsistent with comparable companies will invite scrutiny.

Thus, valuation is never purely about a biotech’s own data. It is also about how the company fits into a broader competitive narrative.

3. Why price targets cluster – or diverge

Investors often note how analyst price targets seem to converge around certain levels. This clustering isn’t coincidental.

Analysts build models using overlapping inputs:

• Peak sales assumptions.
• Development timelines.
• Discount rates.
• Probability adjustments.

When management provides clear, consistent guidance, these inputs become more aligned across the biotech’s covering analysts.

Consider the impact of well-communicated metrics:

• Peak sales guidance helps analysts anchor revenue forecasts instead of relying solely on external datasets.
• Clear clinical timelines reduce variability in launch assumptions and cash burn projections.
• Regulatory strategy clarity narrows uncertainty around approval pathways.

In the absence of clear guidance, analysts fill the gaps with their own assumptions – often leading to a wide dispersion of price targets. With sufficient guidance, models begin to converge.

4. Discount rates and risk premiums

Beyond probability adjustments, analysts also apply higher discount rates to biotech cash flows than they would to mature industries. Long development timelines, binary clinical events, and financing risk all justify a premium.

Consequently, two analysts may agree on a biotech’s peak sales, yet arrive at very different price targets simply because one uses a 10% discount rate while another uses a 12% rate.

5. What analysts cannot model perfectly

Despite the “rigor” of equity analyst’s models, several important factors remain difficult to quantify:

• Competitive landscape shifts.
• Changes in reimbursement or pricing dynamics.
• M&A speculation.
• Investor sentiment cycles.

This is where qualitative judgment enters the equation. Analysts speak to physicians, key opinion leaders, and investors to refine/tweak assumptions that spreadsheets alone cannot capture.

6. Practical advice for management teams

Provide structure without dictating outcomes: Offer ranges for timelines and commercial potential rather than rigid forecasts.

Understand your peers: Analysts are constantly benchmarking you – know who you are being compared to and why.

Engage on probability: Help analysts understand why your asset’s risk profile may differ from historical averages.

Avoid valuation arguments: Analysts rarely respond well to companies pushing specific price targets. Focus on inputs, not outputs, and accept that management teams are incentivized to be bullish, while analysts are incentivized to be more conservative.